Home / Regulation Tracker / FDA Compounding Rulings in 2025: A Peptide-Focused Recap

FDA Compounding Rulings in 2025: A Peptide-Focused Recap

Updated 2026-09-03

A plain-language recap of how FDA compounding policy affecting peptides moved through 2025, with pointers to where to verify the current record.

The short answer

Through 2025, FDA policy on compounded peptides continued to run through the same structure it has used for several years: bulk drug substance nominations reviewed by the FDA and its Pharmacy Compounding Advisory Committee (PCAC), sorted into safety-risk categories that determine whether 503A pharmacies and 503B outsourcing facilities may use a given substance. This page recaps that structure and how it is reported to have applied to peptides during 2025, while flagging the specific dates and vote outcomes that need direct confirmation on the FDA's own published record.

Why this comes up

Peptide researchers, clinicians, and patients following the compounding landscape often want a single timeline of "what changed" in a given year, because bulk substance categorizations, guidance updates, and warning letters can each affect whether a specific peptide stays available through a licensed pharmacy. A yearly recap page is useful for orientation, but because the underlying FDA record updates on its own schedule and this page is written from outside that process, every specific claim below should be treated as a starting point for the reader's own check of the FDA's current published materials rather than a final answer.

Current regulatory status

The FDA's review of nominated bulk drug substances for the 503A list, and the related list for 503B outsourcing facilities, is an ongoing process rather than a single annual event. The agency periodically reopens nomination periods, refers particular substances to the PCAC for a public meeting and vote, and then publishes its own determination, which can affirm, narrow, or update a substance's category. Peptides that had already drawn safety-risk category placements in earlier review cycles, including BPC-157 and several growth-hormone-releasing peptide compounds, remained subject to that same treatment as a baseline heading into 2025, absent a documented change.

Reports connected to 2025 activity describe continued FDA attention to compounded GLP-1 receptor agonist copies, following the broader national conversation about semaglutide and tirzepatide shortages and the compounding activity that expanded around those shortages. Separately from the peptide-specific bulk substances review, FDA guidance on compounding during and after a drug shortage designation is its own distinct legal track, and readers researching a specific GLP-1 compounding question should treat that shortage-compounding framework as a separate topic from the peptide bulk-substances category system described on this site's /regulation/fda-category-2-list-explained/ page. Because the precise 2025 milestones, vote dates, and any newly categorized peptide names are not independently confirmed within the scope of this article, they are listed in the "What to verify" section below rather than stated here as settled fact.

Common misconceptions

A recap article is a substitute for the FDA's own published list. Any list of peptides and their categories is a snapshot that can be out of date by the time it is read. The FDA's current published bulk drug substances lists are the source of record.

"Under FDA review" means a peptide is currently permitted. A substance under active review by the PCAC or FDA staff has not necessarily been cleared for compounding use; the review process itself does not grant interim permission.

All 2025 compounding news relates to peptides specifically. Much of the FDA's 2025 compounding-related activity, including shortage-related guidance for GLP-1 receptor agonists, concerns small-molecule drugs rather than the peptide compounds this site otherwise covers, and the two topics should not be conflated when reading news coverage.

What this means for you

A reader trying to understand where a specific peptide stood at the end of 2025 should go directly to the FDA's current bulk drug substances list for the relevant section, 503A or 503B, rather than relying on any single recap, including this one. Readers working with a pharmacy or clinic can also ask that pharmacy directly which category, if any, applies to a peptide of interest as of the date of the conversation, since a pharmacy that regularly compounds is generally tracking these categorizations as part of its own compliance obligations.

Questions to bring to a pharmacist or clinician

• Which category, if any, does the FDA currently assign to the specific peptide I am asking about, and when was that category last reviewed?
• Is the pharmacy or facility I am considering a licensed 503A pharmacy or a registered 503B outsourcing facility, and can that be confirmed independently?
• Has any state-specific restriction been layered on top of the federal category status for this substance in the state where the pharmacy operates?
• If the peptide relates to a GLP-1 receptor agonist compound, is any shortage-related compounding allowance currently in effect, and when is it expected to be reassessed?

FAQ

Did the FDA ban any peptides outright in 2025? The FDA's bulk drug substances framework does not use the word "ban" the way a scheduling action would. Instead, a peptide can be excluded from compounding by being placed in a safety-risk review category, which functions as a practical bar for 503A and 503B pharmacies. Specific 2025 category decisions should be confirmed on the FDA's current published lists rather than assumed from this recap.

Where does the FDA publish the outcome of these reviews? The FDA publishes bulk drug substance category lists and related guidance documents on its human drug compounding pages, and meeting materials and transcripts from its Pharmacy Compounding Advisory Committee (PCAC) are posted separately when a public meeting is held.

Does a 2025 ruling automatically apply the same way in every state? FDA bulk drug substance decisions apply to federal law governing 503A and 503B compounding nationwide, but pharmacy licensing and practice standards remain layered with state board of pharmacy rules, so a state can add its own restrictions on top of the federal framework.

How is this different from the 2026 update page? This page recaps the 2025 policy record as background. /regulation/fda-compounding-rulings-2026-update/ is scoped to changes reported specifically during 2026 and is the page to check for the most recent status.

Sources

• FDA, "Drugs Compounded and the Federal Food, Drug, and Cosmetic Act" -- https://www.fda.gov/drugs/human-drug-compounding/drugs-compounded-and-federal-food-drug-and-cosmetic-act
• FDA, "FDA Issues List of Bulk Drug Substances Outsourcing Facilities May Use to Compound Under Section 503B" -- https://www.fda.gov/drugs/human-drug-compounding/fda-issues-list-bulk-drug-substances-outsourcing-facilities-may-use-compound-under-section-503b

Readers who want a single habit to take from this recap: treat any year-stamped compounding article, including this one, as a starting index rather than a final answer, and always finish the check on the FDA's own current page before making a decision that depends on a peptide's exact legal status.

Disclaimer

This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.